Finance and funding: latest news

Finance and funding features

Finance and funding news from aidsmap

More news

Finance and funding news selected from other sources

  • Egypt: New Treatments May Defuse Viral Hepatitis Time Bomb

    Egypt is said officially to have the highest prevalence of hepatitis C in the world, with 10 to 14 percent of its 85 million people infected, and about two million in dire need of treatment. The Egyptian government recently struck a deal with U.S. pharmaceutical firm Gilead Sciences to purchase its new hepatitis C pill Sovaldi at a fraction of its American price.

    10 April 2014 | Inter Press Service
  • HIV's Grip on the American South

    One of the strangest things about the H.I.V. epidemic in the Deep South—from Louisiana to Alabama to Mississippi—is how easily most Americans have elided it, choosing instead to imagine that the disease is now an out-there, elsewhere epidemic.

    10 April 2014 | The New Yorker
  • Gilead Sciences: How serious is the pricing problem?

    There really isn’t much precedent at all for branded companies competing on price in a MAJOR (~double digit) way. Plenty of companies play around with rebates and discounts, but it’s rare that the net price difference between major brands is more than a few percentage points.

    09 April 2014 | Barron's
  • Express Scripts Raises Pressure on Gilead for Drug Price

    Express Scripts Holding Co. (ESRX), a pharmacy benefit manager that handles more than 1 billion prescriptions annually in the U.S., is ratcheting up its effort to force Gilead Sciences Inc. (GILD) to cut the $84,000 price of its new hepatitis C pill Sovaldi.

    08 April 2014 | Bloomberg
  • Briefing: Punitive aid cuts disrupts healthcare in Uganda

    Since the enactment of a draconian anti-homosexuality bill in Uganda just over a month ago, donors have been slashing or suspending aid to the country in protest. Health officials, activists and NGOs warn that this could have a major impact on healthcare services, particularly for HIV/AIDS patients.

    08 April 2014 | IRIN
  • Costs to public of $84,000 hep C drug ‘outrageous' - Kaiser Permanente

    Kaiser Permanente, the biggest U.S. health maintenance organization, said it is using Gilead Sciences' new hepatitis C drug, Sovaldi, even though its $84,000 treatment price is "outrageous."

    03 April 2014 | Reuters
  • International HIV as Prevention Workshop: Day 1 summary

    This year’s International HIV Treatment as Prevention Workshop began with an opening roundtable session that gathered high-level delegates from across the globe. The goal of the panel: to bring together the key national decision-makers and pivotal international partners to explore the importance of new HIV treatment targets.

    02 April 2014 | Treatment as Prevention Workshop
  • How ACA affects vulnerable Americans living with HIV/AIDS

    A series of papers recently published examines how the Affordable Care Act could affect two sectors of the most vulnerable Americans -- those living with HIV/AIDS and people who have recently cycled through jail.

    02 April 2014 | Science Daily
  • HIV Testing Counselor Sells 'Truvada Whore' Shirts For AIDS Charity

    Adam Zebowski, an HIV test counselor at the San Francisco AIDS Foundation, is selling #TruvadaWhore t-shirts at a Kickstarter-style site to help meet his AIDS/Lifecycle fundraising goal of $3000.

    01 April 2014 | Towelroad (blog)
  • Gilead says has discounted hepatitis C drug for some health plans

    Gilead Sciences Inc, under fire for pricing a new hepatitis C drug at $1,000 a pill, has discount agreements with a number of health insurers, a company executive said in an interview.

    31 March 2014 | Reuters
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.